The US Army has awarded a contract to AVI BioPharma for the development of new platform-based solutions to counter biological threats.

Under the contract worth around $291m, the company will develop therapeutic candidates, AVI-6002 and AVI-6003, for ebola and marburg viral fevers respectively.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The six-year contract is part of the US Department of Defense chemical and biological defence programme, Transformational Medical Technologies (TMT).

Around $80m of the contract will be spent on phase 1 studies in healthy volunteers as well as preclinical studies for a period of more than 18 months.

AVI-6002 and AVI-6003 are RNA-based therapeutic candidates that use the company’s PMOplus chemistry.

The remedies have demonstrated reproducible high rates of survival in ebola and marburg virus-infected animals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The TMT programme was developed to produce a wide range of medical countermeasures to protect the soldiers from emerging and genetically altered biological threats.

Army Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Army Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact across the defence sector.

Excellence in Action
Virtualitics has clinched both the Innovation and Business Expansion awards for its Integrated Readiness Optimization (IRO) AI suite, transforming maintenance, sustainment and operational decision-making across the US DoD. Discover how explainable AI and predictive insights are redefining mission readiness, risk management and joint-force efficiency.

Discover the Impact